Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Trial Shows XTANDI Significantly Improved Radiographic PFS in Metastatic Hormone-Sensitive Prostate Cancer

americanpharmaceuticalreviewFebruary 13, 2019

Tag: mHSPC , Xtandi , PFS , ARCHES trial

PharmaSources Customer Service